Hikma Pharmaceuticals PLC (LON:HIK) has announced that Riad Mishlawi is today stepping down as Chief Executive Officer (CEO) and from Hikma’s Board of Directors by mutual agreement.
Said Darwazah, Hikma’s Executive Chairman and former CEO, will assume all CEO responsibilities with immediate effect. In addition, Khalid Nabilsi, Hikma’s Chief Financial Officer, will join Hikma’s Board of Directors and take on additional management responsibilities to further strengthen the Group’s focus on delivering its strategic plans.
Said Darwazah said: “I would like to thank Riad for his contributions over his long career at Hikma and we wish him well for the future. I look forward to continuing to work closely with Hikma’s Executive Committee and with Khalid in his expanded role to deliver on our strategic plans.”
Victoria Hull, Hikma’s Senior Independent Director said: “The Board is confident in Hikma’s future growth prospects under the experienced leadership of Said, supported by Hikma’s talented global team. We will be launching a search for a new CEO in due course.”
Riad Mishlawi said: “I’d like to thank Said and all my Hikma colleagues. It has been an honour to work alongside you and, as I move into retirement, I wish you continued growth and every success.”
Group guidance for 2025 remains unchanged from the 6 November 2025 trading update and Hikma will report its 2025 full year results on 26 February 2026.
